The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The German firm grew revenues to €5.3 million for the first nine months of the year from €976,000 a year ago, but its net loss expanded 48 percent year over year.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
